Physician profile
Cecelia Koetting
NPI 1174864318
$457,786.74
in general payments reported to CMS, 2019-2025
39 companies · $187K in 2025
The $187K reported for 2025 was more than what 99% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,021 · 2020: $5,212 · 2021: $28K · 2022: $40K · 2023: $63K · 2024: $132K · 2025: $187K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $140K · Consulting Fee: $117K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $71K · Travel and Lodging: $38K · Food and Beverage: $17K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $139,530.00 |
| Consulting Fee | $116,555.76 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $71,394.90 |
| Travel and Lodging | $38,208.90 |
| Food and Beverage | $16,606.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $127,958.19 | 2022-2025 | Miebo, Xiidra, Blink Nutritears |
| Dompe US, INC. | $97,591.24 | 2020-2025 | Oxervate |
| Tarsus Pharmaceuticals, INC. | $65,875.20 | 2024-2025 | Xdemvy |
| Alcon Vision LLC | $45,027.12 | 2019-2025 | Tryptyr, Systane, Total30 |
| Oyster Point Pharma, INC. | $22,897.71 | 2022-2024 | Tyrvaya, Ryzumvi |
| Alcon Research LLC | $20,570.00 | 2022-2025 | Tryptyr |
| Abbvie INC. | $18,963.01 | 2022-2025 | |
| Eyevance Pharmaceuticals LLC | $10,558.93 | 2020-2023 | Flarex |
| Sight Sciences, INC. | $8,653.58 | 2019-2024 | Tearcare System |
| Harrow Eye, LLC | $6,295.84 | 2024-2025 | Vevye, Triesence |
| Ivantis, INC | $5,243.67 | 2021 | |
| Thea Pharma INC. | $4,957.59 | 2022-2024 | Iyuzeh |
| Glaukos Corporation | $4,478.73 | 2020-2025 | Ce-Marked Kxla System, Photrexa Viscous and Photrexa, Idosetr |
| Kala Pharmaceuticals, INC. | $2,470.09 | 2019-2022 | |
| Horizon Therapeutics Plc | $2,217.62 | 2019-2020 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cecelia Koetting listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.